1. Introduction {#sec1-marinedrugs-13-06306}
===============

Mangrove is a specialized marine ecosystem. Mangrove endophytic fungi have drawn a lot of attention for the past few years as a rich source of bioactive and novel compounds \[[@B1-marinedrugs-13-06306],[@B2-marinedrugs-13-06306]\]. In the course of our exploration for the metabolites of endophytic fungi from the mangrove in the South China Sea, numerous new compounds were obtained \[[@B3-marinedrugs-13-06306],[@B4-marinedrugs-13-06306],[@B5-marinedrugs-13-06306]\]. In this study, six new compounds, peaurantiogriseols A--F (**1**--**6**), along with two known compounds, aspermytin A (**7**) and 1-propanone,3-hydroxy-1-(1,2,4a,5,6,7,8,8a-octahydro-2,5-dihydroxy-1,2,6-trimethyl-1-naphthalenyl) (**8**), were isolated from endophytic fungus *Penicillium aurantiogriseum* 328\# from the bark of mangrove plant *Hibiscus tiliaceus*. Compounds **1**--**8** ([Figure 1](#marinedrugs-13-06306-f001){ref-type="fig"}) had similar polyketide decalin scaffolds substituted by 3-oxopropanol side chains, and shown low inhibitory activity against 6×His-tagged recombinant human aldose reductase. Here, we report the isolation and structural elucidation of compounds **1**--**8** based on the studies of their NMR, EI-MS, and ECD spectra.

![The chemical structures of compounds **1**--**8**.](marinedrugs-13-06306-g001){#marinedrugs-13-06306-f001}

2. Results and Discussion {#sec2-marinedrugs-13-06306}
=========================

Peaurantiogriseol A (**1**, [Figure 1](#marinedrugs-13-06306-f001){ref-type="fig"}) was obtained as a colorless solid and had a molecular formula of C~16~H~26~O~3~ as determined by HREIMS data (observed *m*/*z* 266.1878 M^+^, calculated 266.1876), requiring 4° of unsaturation. The ^13^C-NMR and DEPT spectra ([Table 1](#marinedrugs-13-06306-t001){ref-type="table"}) indicated the presence of a carbonyl group (δ 215.4), two olefinic carbons, four *sp*^3^ CH~2~ groups, five *sp*^3^ CH groups, one *sp*^3^ quaternary carbon atom, and three methyl groups. The ^1^H-NMR and ^1^H--^1^H COSY spectra ([Table 1](#marinedrugs-13-06306-t001){ref-type="table"} and [Figure 2](#marinedrugs-13-06306-f002){ref-type="fig"}) showed the signals of a 3-oxopropanol system (δ~H~ 3.82/2.64), and a *cis* double bond signals (δ~H~ 5.91 d *J* = 10.6 Hz; 5.58 ddd *J* =10.6, 4.8, 2.4 Hz). The remaining 2° of unsaturation supported a decalin segment in **1**. In the HMBC spectrum ([Figure 2](#marinedrugs-13-06306-f002){ref-type="fig"}), rich correlation data allowed us to unambiguously establish the locations of substituents on the decalin ring. A methyl singlet at δ~H~ 1.19 correlated with C-3 and C-5 respectively, which revealed that the methyl group, with the 3-oxopropanol side chain, was located at C-4 position. A methyl doublet signals at δ~H~ 0.75 (*J* = 8.4 Hz) correlated with C-13 and C-12, and another methyl doublet signals at δ~H~ 1.00 (*J* = 9.6 Hz) correlated with C-9 and C-7, revealing that the two methyl groups were located at C-8 and C-13 positions, respectively. Based on the HMBC correlations of H-11/C-9 and H-12/C-14, the *cis* double bond was easily assigned as C-11 and C-12. One hydroxyl group was identified at C-9 position based on the chemical shift of CH-9 (δ 2.89/79.3) and HMBC correlations.

![The key ^1^H--^1^H COSY and HMBC correlations of compounds **1**--**5**.](marinedrugs-13-06306-g002){#marinedrugs-13-06306-f002}

The relative stereochemistry of **1** was established by its NOESY spectrum ([Figure 3](#marinedrugs-13-06306-f003){ref-type="fig"}). The NOE correlations of H-15/H-10, H-15/H-13 and H-14/H-5 confirmed a *trans*-fused decalin ring in **1**. Methyl-15 and OH-9 were oriented on the same side of the decalin ring, and methyl-14 and methyl-16 were oriented on the other side based on the NOE correlations of H-8/H-10 and H-16/H-9.

The absolute configuration of **1** was determined by comparison of the ^1^H-NMR spectra of corresponding (*R*) and (*S*)-Mosher esters ([Figure 4](#marinedrugs-13-06306-f004){ref-type="fig"}; [Supplementary Materials Table S2](#marinedrugs-13-06306-s001){ref-type="supplementary-material"}). OH-1 of compound **1** was mainly esterified by *S*/*R*-MTPA-Cl based on the larger chemical shift of H-1. There was an esterified C-1 hydroxyl group in Mosher esters of **1**, which were confirmed by their ^19^F NMR spectra that showed 2 CF~3~ signals ([Supplementary Materials Figure S8](#marinedrugs-13-06306-s001){ref-type="supplementary-material"}). The preferred conformations of Mosher esters of **1** dominating ^1^H NMR spectroscopic features were that the 3-oxopropanol side chains with MTPA moiety were in equatorial position, and bend to C-13 position; CH~2~-1--O--C=O--CF~3~ substructure of Mosher esters of **1** were coplanar ([Figure 4](#marinedrugs-13-06306-f004){ref-type="fig"}). The shielding or deshielding effects of the phenyl rings of MTPA moiety on H-13 or H-14 were larger in its *R*-Mosher ester than that of *S*-Mosher ester. The absolute configuration of C-13 in **1** was deduced as *S*-configuration based on the positive chemical shift differences (Δδ*^SR^*) of H-13 and negative chemical shift differences (Δδ*^SR^*) of H-14 from corresponding Mosher esters \[[@B6-marinedrugs-13-06306],[@B7-marinedrugs-13-06306]\]. Finally, the absolute configuration of **1** was confirmed as (4*S*,5*S*,8*S*,9*R*,10*R*,13*S*)-configuration ([Figure 1](#marinedrugs-13-06306-f001){ref-type="fig"}) based. The absolute configuration of **1** was validated by the result that the experimental data and calculated ECD spectrum for (4*S*,5*S*,8*S*,9*R*,10*R*,13*S*)-configuration of **1** matched exactly ([Figure 5](#marinedrugs-13-06306-f005){ref-type="fig"}).

marinedrugs-13-06306-t001_Table 1

###### 

^1^H and ^13^C NMR data of compounds **1**--**5** (400/100 MHz in CDCl~3~, *J* in Hz).

  ------- ------------------------- ------------------------- ------------------------- ------------------------- --------- ------------------------ ------------------------- ------------------------- -------------------------- --------------------------
          **1 ^α^**                 **2**                     **3**                     **4**                     **5**                                                                                                             
  ^13^C   ^1^H                      ^13^C                     ^1^H                      ^13^C                     ^1^H      ^13^C                    ^1^H                      ^13^C                     ^1^H                       
  1       58.0 t                    3.82 m                    57.9 t                    3.80 m                    58.2 t    3.82 m                   58.4 t                    3.82 m                    61.2 t                     4.08 dd 12.0, 8.0
                                                                                                                                                                                                         3.87 dt 12.0, 2.8          
  2       41.0 t                    2.64 ddd 18.6, 6.6, 4.2   41.0 t overlapped         2.68 ddd 18.4, 6.0, 4.8   40.9 t    2.66 q 4.4               44.1 t                    3.11 ddd 18.8, 6.4, 3.6   39.5 t                     2.79 ddd 14.0, 12.8, 8.0
          2.63 ddd 18.6, 6.6, 4.2                             2.61 ddd 18.4, 6.0, 4.8                                                                2.67 ddd 18.8, 6.4, 3.6                             2.19 ddd 14.0, 12.8, 8.0   
  3       215.4 s                                             215.6 s                                             215.8 s                            216.1 s                                             212.6 s                    
  4       52.3 s                                              52.3 s                                              52.4 s                             57.2 s                                              57.1 s                     
  5       45.3 d                    1.66 m                    39.0 d                    1.59 m                    38.7 d    1.58 m                   43.3 d                    1.78 m                    43.0 d                     2.23 m
  6       26.8 t                    1.54 m                    26.7 t                    1.68 m                    23.0 t    1.53 m                   23.1 t                    1.42 m                    25.8 t                     1.14 m
          0.91 m                                              0.91 m                                              1.26 m                             1.31 m                                                                         
  7       33.5 t                    1.16 m,                   29.8 t                    1.80 m                    45.8 t    1.71 m                   39.5 t                    1.67 m                    29.6 t                     1.83 m
                                    1.71 m                                              1.08 m                              1.27 m                                             1.50 m                                               1.02 m
  8       41.0 d                    1.36 m                    41.0 d overlapped         1.58 m                    70.2 s                             70.1 s                                              40.8 d                     1.62 m
  9       79.3 d                    2.89 t 9.6                36.3 t                    1.84 m                    39.7 t    1.65 m                   45.3 t                    1.74 m                    35.4 t                     1.94 m
                                                                                        0.86 m                              1.53 m                                             1.25 m                                               1.03 m
  10      36.6 d                    1.67 m                    37.9 d                    1.69 m                    33.6 d    2.13 m                   33.7 d                    2.24 tt 11.8, 2.8         37.4 d                     1.82 m
  11      125.0 d                   5.91 d 10.6               129.6 d                   5.32 d 10.0               129.6 d   5.32 d 9.6               131.0 d                   5.34, s                   134.3 d                    5.66 dd 9.6, 1.2
  12      130.6 d                   5.58 ddd 10.6, 4.8, 2.4   129.7 d                   5.45 ddd 10.0, 4.8, 2.4   130.0 d   5.52 ddd 9.6, 4.8, 2.8   133.6 d                   5.34, s                   130.6 d                    5.52 dd 9.6, 2.8
  13      39.5 d                    2.01 m                    39.9 d                    2.06 m                    40.0 d    2.09 m                   74.0 s                                              78.5 s                     
  14      18.6 q                    0.75 d 8.4                18.7 q                    0.72 d 7.2                18.8 q    0.75 d 7.2               27.5 q                    1.13 s                    20.5 q                     1.18 s
  15      17.5 q                    1.19 s                    17.4 q                    1.17 s                    17.7 q    1.22 s                   12.1 q                    1.33 s                    11.2 q                     0.88 s
  16      18.7 q                    1.00 d 9.6                68.3 t                    3.44 dd 10.8, 6.4         31.8 q    1.22 s                   31.8 q                    1.25 s                    68.3 t                     3.48 m
                                                              3.41 dd 10.8, 6.4                                                                                                                                                     
  ------- ------------------------- ------------------------- ------------------------- ------------------------- --------- ------------------------ ------------------------- ------------------------- -------------------------- --------------------------

The data were recorded at ^α^ 600 MHz (^1^H-NMR) and 150 MHz (^13^C-NMR).

![The key NOE correlations of compounds **1**--**6**.](marinedrugs-13-06306-g003){#marinedrugs-13-06306-f003}

![(**A**) Chemical shift difference values (Δδ*^SR^* = δ*^S^* − δ*^R^*, in Hz) of compounds **1**/**2** esterified by *S*/*R*-MTPA-Cl; and (**B**) preferred conformations of *S*/*R*-Mosher esters of **1**/**2**.](marinedrugs-13-06306-g004){#marinedrugs-13-06306-f004}

![Calculated and experimental ECD spectra of **1**--**6**.](marinedrugs-13-06306-g005){#marinedrugs-13-06306-f005}

Peaurantiogriseol B (**2**, [Figure 1](#marinedrugs-13-06306-f001){ref-type="fig"}) was obtained as a white solid and had a molecular formula of C~16~H~26~O~3~ based on HREIMS data (observed *m*/*z* 266.1875 M^+^, calculated 266.1876), same as compound **1**. The ^1^H- and ^13^C-NMR spectra of **2** were very similar to those of **1** ([Table 1](#marinedrugs-13-06306-t001){ref-type="table"}), except for the absence of one oxygenated CH-9 group signal, and the change of a doublet signal at δ 1.00/18.7 to hydroxymethyl signals at δ 3.44/3.41/68.3. These results suggested the presence on compound **2** of a hydroxymethyl group at C-16 position. The ^1^H-^1^H COSY and HMBC correlations of **2** were also similar to those of **1** ([Figure 2](#marinedrugs-13-06306-f002){ref-type="fig"}), which confirmed that an OH group was located at C-16.

The relative stereochemistry of **2** was established by its NOESY spectrum ([Figure 3](#marinedrugs-13-06306-f003){ref-type="fig"}). Its NOE data were very similar to those of **1**. A *trans*-fused decalin ring in **2** was indicated by the correlations of H-15/H-13, H-15/H-10, and H-14/H-5. Methyl-15 and methyl-14 were oriented on the opposite side, and hydroxymethyl-16 and methyl-14 were oriented on the same side based on the NOE correlation of H-16/H-5.

The absolute configuration of **2** was determined by comparison of the ^1^H-NMR spectra of its (*R*) and (*S*)-Mosher esters like compound **1**. Both alcohols (OH-1 and OH-16) in **2** were esterified based on the larger chemical shifts of H-1/H-16 ([Supplementary Materials Table S2](#marinedrugs-13-06306-s001){ref-type="supplementary-material"}), which were confirmed based on its ^19^F NMR spectra ([Supplementary Materials, Figure 13S](#marinedrugs-13-06306-s001){ref-type="supplementary-material"}); there were 3 CF~3~ signals in ^19^F NMR spectra of Mosher esters of **2**. The ^1^H NMR spectroscopic features and preferred conformations of Mosher esters of **2** were the same as that of **1**. Therefore, the absolute configuration of **2** was confirmed as (4*S*,5*S*,8*S*,10*R*,13*S*)-configuration ([Figure 1](#marinedrugs-13-06306-f001){ref-type="fig"}). The absolute configuration of **2** was validated by the result that the experimental data and calculated ECD spectrum for (4*S*, 5*S*, 8*S*, 10*R*, 13*S*)-configuration of **2** matched exactly ([Figure 5](#marinedrugs-13-06306-f005){ref-type="fig"}).

Peaurantiogriseol C (**3**, [Figure 1](#marinedrugs-13-06306-f001){ref-type="fig"}) was obtained as a white solid and had a molecular formula of C~16~H~26~O~3~ based on HREIMS data (observed *m*/*z* 248.1770 \[M − H~2~O\]^+^, calculated for C~16~H~24~O~2~, 248.1771). The ^1^H- and ^13^C-NMR spectra of **3** were very similar to those of compound **2** ([Table 1](#marinedrugs-13-06306-t001){ref-type="table"}), except for the changes of hydroxymethyl signals at δ 3.41/68.3 to a methyl singlet at δ 1.22/31.0 in **3**, and CH group signals at δ 1.58/41.0 to quaternary carbon atom signal at δ 70.2 in **3**. These results suggested that compound **3** possesses a hydroxyl group at C-8 position, which were confirmed by the HMBC correlations from H-16 to C-7, and H-16 to C-9 ([Figure 2](#marinedrugs-13-06306-f002){ref-type="fig"}). The relative stereochemistry of **3** was the same as compound **2** based of its NOESY spectrum ([Figure 3](#marinedrugs-13-06306-f003){ref-type="fig"}). The absolute configuration of compound **3** was determined by the result that the experimental data, showing a negative Cotton effect at 291 nm, and calculated ECD spectrum for (4*S*,5*S*,8*S*,10*R*,13*S*)-configuration of **3** matched exactly ([Figure 5](#marinedrugs-13-06306-f005){ref-type="fig"}).

Peaurantiogriseol D (**4**, [Figure 1](#marinedrugs-13-06306-f001){ref-type="fig"}) had a molecular formula of C~16~H~26~O~4~ based on HREIMS data (observed *m*/*z* 282.1824 M^+^, calculated 282.1826), with one more oxygen atom than compound **3**. The ^1^H-NMR, ^13^C-NMR, ^1^H--^1^H COSY, and HMBC correlations of **4** were very similar to those of **3** ([Table 1](#marinedrugs-13-06306-t001){ref-type="table"}, [Figure 2](#marinedrugs-13-06306-f002){ref-type="fig"}), except for the change of a methyl doublet signal at δ 0.75 (d, *J* = 7.2 Hz) to singlet signal at δ 1.13 in **4**, which suggested that compound **4** had an added OH group. The additional OH group was located at C-13 based on the chemical shift of CH-13 (δ~c~ 74.0) and HMBC correlations. The relative stereochemistry of **4** was established based on the result that the interatomic non-bonded distance of key atoms and NOESY correlation signals matched exactly in its 3D model ([Table 2](#marinedrugs-13-06306-t002){ref-type="table"}, Me-eea-*trans* conformer). The relative stereochemistry of **4** was assigned as that methyl-14 and methyl-15 were equatorial; methyl-16 was axial; and the decalin ring was *trans* based on the interatomic non-bonded distance of key atoms less than 4 Å. The *trans*-fused decalin ring of **4** was supported by the coupling constant of CH-10 signal (tt, *J* = 11.8, 2.8 Hz). The absolute configuration of **4** was confirmed as (4*R*,5*S*,8*S*,10*R*,13*R*)-conformer by the result that the experimental data, showing a negative Cotton effect at 298 nm, and calculated ECD spectrum for (4*R*,5*S*,8*S*,10*R*,13*R*)-conformer of **4** matched exactly ([Figure 5](#marinedrugs-13-06306-f005){ref-type="fig"}).

marinedrugs-13-06306-t002_Table 2

###### 

The key NOE correlations of compound **4** and interatomic non-bonded distance of the key atoms in its main 3D conformers.

  Key Atoms   NOE Correlation   Main 3D Conformers              
  ----------- ----------------- -------------------- ---------- ----------
  CH~3~-14    H-5               3.347715             4.256464   3.471439
  CH~3~-15    H-10              3.608014             2.503497   1.862233
  CH~3~-16    H-10              2.310649             5.322337   1.826166
  CH~3~-14    H-2               5.109479             4.964076   2.470492
  CH-5        H-10              2.265362             2.503497   3.087856

Me-aaa-*cis* conformer: methyl-14, methyl-15, and methyl-16 are axial, decalin ring is *cis*, hypothetically; Me-eee-*cis* conformer: methyl-14, methyl-15, and methyl-16 are equatorial, decalin ring is *cis*, hypothetically; Me-eea-*trans* conformer: methyl-14 and methyl-15 are equatorial, and methyl-16 is axial, decalin ring is *trans*, hypothetically.

Peaurantiogriseol E (**5**, [Figure 1](#marinedrugs-13-06306-f001){ref-type="fig"}) had a molecular formula of C~16~H~24~O~3~ based on HREIMS data (observed *m*/*z* 264.1721 M^+^, calculated 264.1720), which was two mass units less than that of compound **2**, requiring 5 degrees of unsaturation. The ^1^H-NMR and ^13^C-NMR data for **5** were similar to those of compound **2** ([Table 1](#marinedrugs-13-06306-t001){ref-type="table"}). The most obvious difference between **5** and **2** was that the absence of one CH group signal at δ 2.06/39.9, and the change of a doublet signal at δ 0.72 to singlet at δ 1.18/20.5 in **5**. These results suggested that a pyrone moiety was formed in **5** by an O--C bond at C-13 position, which was supported by the HMBC correlations from H-1 to C-13 ([Figure 2](#marinedrugs-13-06306-f002){ref-type="fig"}), and, from H-2 to C-4.

The relative stereochemistry of **5** was established by its NOESY spectrum ([Figure 3](#marinedrugs-13-06306-f003){ref-type="fig"}). A *cis*-fused decalin ring in **5** was confirmed based on the NOE correlations of H-15/H-10, H-14/H-5, and H-15/H-14. Methyl-14, methyl-15, and hydroxymethyl-16 were oriented on the same side by the NOE correlations between H-16 and H-10. The absolute configuration of **5** was determined based on the result that the experimental ECD spectrum, showing a negative Cotton effect at 298 nm, and calculated ECD spectrum for (4*R*,5*R*,8*R*,10*R*,13*S*)-configuration of compound **5** matched exactly ([Figure 5](#marinedrugs-13-06306-f005){ref-type="fig"}).

Peaurantiogriseol F (**6**, [Figure 1](#marinedrugs-13-06306-f001){ref-type="fig"}) had a molecular formula of C~16~H~26~O~4~ based on HRESIMS data (observed *m*/*z* 283.18999 \[M + H\]^+^, calculated for C~16~H~26~O~4~, 283.19039 \[M + H\]^+^), with the same planar structure as that of known craterellone D based on its spectroscopic data ([Supplementary Materials Table S1](#marinedrugs-13-06306-s001){ref-type="supplementary-material"}) \[[@B8-marinedrugs-13-06306]\]. The $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ of compound **6** was +21 (*c* 2.2, MeOH) with opposite sign of craterellone D. The NOE correlations of H-14/H-15, H-14/H-5, H-14/H-10, H-15/H-5, and H-15/H-10 allowed us to unambiguously establish a *cis-*fused decalin ring in **6** different from the *trans* junction of craterellone D. Hydroxymethyl-16 were oriented on the opposite side of methyl-14/methyl-15 based on the NOE correlation of H-8/H-10. Compound **6** is a diastereoisomer of craterellone D. The absolute configuration of **6** was determined based on the result that the experimental ECD spectrum, showing a negative Cotton effect at 296 nm, and calculated ECD spectrum for (4*S*,5*S*,8*R*,10*S*,13*R*)-configuration of **6** matched exactly ([Figure 5](#marinedrugs-13-06306-f005){ref-type="fig"}).

Compound **7** was identified as aspermytin A by comparison of its spectral data with \[[@B9-marinedrugs-13-06306]\]; both compound **7** and aspermytin A had the same NMR, MS and specific rotation data.

The structure of compound **8** ([Figure 1](#marinedrugs-13-06306-f001){ref-type="fig"}) was also elucidated by its spectroscopic data ([Supplementary Materials Table S1](#marinedrugs-13-06306-s001){ref-type="supplementary-material"}). Its $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ was −29 (*c* 2.1, MeOH). Its *trans-*fused decalin ring was determined based on the NOE correlations of H-14/H-5 and H-15/H-10; its methyl-14 and hydroxyl-9 were oriented on the opposite side of methyl-15 and methyl-16 by the NOE correlations of H-15/H-10, H-16/H-10, and H-16/H-9. It was found that the planar structure of compound **8** was the same as that of known 1-propanone, 3-hydroxy-1-(1,2,4a,5,6,7,8,8a-octahydro-2,5-dihydroxy-1,2,6-trimethyl-1-naphthalenyl), CAS Registry Number 1235005-17-0. No reference, nor stereochemical information are presented in SciFinder.

Compounds **1**−**8**, at a concentration of 50 mM, showed low inhibitory effect against human aldose reductase; the corresponding value of percent inhibition were 16%, 6%, 31%, 22%, 26%, 2%, 13%, and 9%. The compounds showed no activity of inducing neurite outgrowth (PC-12) \[[@B9-marinedrugs-13-06306]\], nor antimicrobial activity against *E. coli.* (ATCC 25922), *Staphylococcu aureus* (ATCC 25923), and *Candida albicans* (ATCC 60193), at a concentration of 128 μg/mL.

3. Experimental Section {#sec3-marinedrugs-13-06306}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-13-06306}
------------------------------------

(*R*)-(−)-α-Methoxy-α-trifluoromethylphenylacetyl chloride (MTPA-Cl) (99%), (*S*)-(+)-MTPA-Cl (99%), dimethyl sulfoxide, and pyridine-*d*~5~ (99.5%) were purchased from Sigma (St. Louis, MO, USA). 6×His-tagged recombinant human aldose reductase was presented by Xiaopeng Hu, School of Pharmaceutical Sciences, Sun Yat-sen University \[[@B10-marinedrugs-13-06306]\]; its substrate, β-NADPH were purchased from Sigma-Aldrich (St. Louis, MO, USA); methanol was HPLC grade; other reagents were analytical grade and commercially available; PDA medium were purchased from Beijing Land Bridge Technology Co., Ltd, Beijing, China.

Optical rotation measurements were carried out using a Bellingham-Stanley 37--440 polarimeter (Bellingham Stanley Ltd., Kent, UK). UV spectra were determined using a UV-240 spectrophotometer (Shimadzu, Tokyo, Japan). ECD spectra were measured using a Chirascan Circular Dichroism Spectrometer (Applied PhotoPhysics, Surrey, UK). IR spectra were measured on a TENSOR37 spectrometer (Bruker Optics, Ettlingen, Germany). The ^1^H-NMR and ^13^C-NMR data were acquired using a Bruker Avance 400 spectrometer at 400 MHz for ^1^H nuclei and 100 MHz for ^13^C nuclei, a Bruker Avance III 500 MHz NMR spectrometer at 470 MHz for ^19^F nuclei, and a Bruker Avance III 600 MHz NMR spectrometer at 600 MHz for ^1^H nuclei and 150 MHz for ^13^C nuclei (Bruker Biospin, Rheinstetten, German). TMS was used as an internal standard, and the chemical shifts (δ) were expressed in ppm or Hz. The EI mass spectra and high-resolution mass spectra were obtained using MAT95XP (ThermoFinnigan, Bremen, Germany) high resolution mass spectrometer and a LTQ-Orbitrap LC-MS (Thermo Fisher, Frankfurt, German). HPLC was performed using a 515 pump with a UV 2487 detector (Waters, Milford, MA, USA) and an Ultimate XB-C-18 column (250 mm × 10 mm, 5 μm; Welch, MD, USA). Normal pressure preparative column chromatography was carried out on RP-18 gel (25--40 μm, Daiso Inc., Osaka, Japan), silica gel (200--400 mesh, Qingdao Marine Chemical Inc., Qingdao, China), or Sephadex-LH-20 (GE Healthcare, Stockholm, Sweden) for reverse and direct phase elution modes, respectively. TLC was performed over F~254~ glass plates (Qingdao Marine Chemical Inc., Qingdao, China) and analyzed under UV light (254 and 366 nm).

3.2. Fungal Material {#sec3dot2-marinedrugs-13-06306}
--------------------

Endophytic fungus *Penicillium aurantiogriseum* 328\# was isolated with PDA medium from the bark of *Hibiscus tiliaceus* collected in the Qi'ao Mangrove Nature Reserve of Guangdong Province, China and identified according to its morphological characteristics and the ITS region \[[@B11-marinedrugs-13-06306]\]. A voucher specimen is deposited in our laboratory at −20 °C.

3.3. Fermentation, Extraction and Isolation {#sec3dot3-marinedrugs-13-06306}
-------------------------------------------

Small agar slices bearing mycelia were placed in 1000 mL Erlenmeyer flasks containing rice medium (composed of 60 g rice, 80 mL distilled water, and 0.24 g sea salt); and incubated for 30 days at 28 °C. In total, 120 flasks of culture were obtained. Cultures were extracted with EtOAc. In total, 200 g crude extract was obtained by evaporation of EtOAc. The crude extract was suspended in H~2~O (2 L) and partitioned with *n*-hexane (3 L × 2) and EtOAc (3 L × 2) to give *n*-hexane (90 g) and EtOAc (51 g) extracts, respectively.

The EtOAc extract was subjected to silica gel column, eluted with *n*-hexane--EtOAc gradient (from 100:0 to 0:100) to obtain six fractions (Frs. 1--6). Fr. 2 (7.5 g) was subjected to column chromatography over silica gel, eluted with *n*-hexane--EtOAc (50:50) to obtain three fractions (Frs. 2.1--2.3). Frs. 2.1 and Frs. 2.2 were purified by Sephadex LH-20 (MeOH) to yield compound **1** (67.5 mg) and compound **7** (1.007 g), respectively; Fr. 2.3 was separated by HPLC (MeOH-H~2~O, 20:80, 2 mL/min, 254 nm) to isolate compound **5** (6 mg). Fr. 3 (4.5 g) was purified using a Sephadex LH-20 column (MeOH) and separated by HPLC (MeOH-H~2~O gradient from: 25:75 to 50:50, 2 mL/min, 254 nm) to yield compound **3** (40 mg) and compound **2** (45 mg). Fr. 4 (7.7g) was subjected to column chromatography over silica gel, eluted with *n*-hexane--EtOAc (40:69) to obtain two fractions, Fr. 5.1 and Fr. 5.2. Fr. 5.1 purified using Sephadex LH-20 (MeOH) to yield compound **6** (206 mg); and Fr. 5.2 was separated by HPLC (MeOH-H~2~O, 20:80, 2 mL/min, 254 nm) to yield compound **4** (4 mg) and compound **8** (27.1 mg).

3.4. Spectral Data {#sec3dot4-marinedrugs-13-06306}
------------------

Peaurantiogriseol A (**1**): colorless solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ +73 (*c* 1.5, MeOH); UV (MeOH) λ~max~ (logε) 240 (2.4) nm; ECD (MeOH) Δε~249~ −0.36; IR (KBr) ν~max~ 3425, 1703 cm^−1^; for ^1^H-NMR and ^13^C-NMR data, see [Table 1](#marinedrugs-13-06306-t001){ref-type="table"}; EIMS *m*/*z* 266 (M^+^), 248, 217, 203, 193; HREIMS *m*/*z* 266.1878 \[M^+^\] (calculated for C~16~H~26~O~3~, 266.1876).

Peaurantiogriseol B (**2**): colorless solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ +89 (*c* 1.7, MeOH); UV (MeOH) λ~max~ (logε) 240 (3.1) nm; ECD (MeOH) Δε~249~ −0.49; IR (KBr) ν~max~ 3431, 1701 cm^−1^; for ^1^H-NMR and ^13^C-NMR data, see [Table 1](#marinedrugs-13-06306-t001){ref-type="table"}; EIMS *m*/*z* 266 \[M^+^\]; HREIMS *m*/*z* 266.1875 \[M^+^\] (calculated for C~16~H~26~O~3~, 266.1876).

Peaurantiogriseol C (**3**): colorless solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ +60 (*c* 0.5, MeOH); UV (MeOH) λ~max~ (logε) 250 (2.1) nm; ECD (MeOH) Δε~291~ −0.21; IR (KBr) ν~max~ 3434, 1701 cm^−1^; for ^1^H-NMR and ^13^C-NMR data, see [Table 1](#marinedrugs-13-06306-t001){ref-type="table"}; EIMS *m*/*z* 248 (M-H~2~O)^+^, 206, 175; HREIMS *m*/*z* 248.1770 \[M − H~2~O\]^+^ (calculated for C~16~H~24~O~2~, 248.1771).

Peaurantiogriseol D (**4**): white solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ +18 (*c* 0.4, MeOH); UV (MeOH) λ~max~ (logε) 282 (2.6) nm; ECD (MeOH) Δε~298~ −0.88; IR (KBr) ν~max~ 3434, 1688 cm^−1^; for ^1^H-NMR and ^13^C-NMR data, see [Table 1](#marinedrugs-13-06306-t001){ref-type="table"}; EIMS *m*/*z* 282 \[M^+^\]; HREIMS *m*/*z* 282.1824 \[M^+^\] (calculated for C~16~H~26~O~4~, 282.1826).

Peaurantiogriseol E (**5**): colorless solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ −153 (*c* 1.5, MeOH); UV (MeOH) λ~max~ (logε) 282 (2.0) nm; ECD (MeOH) Δε~298~ −2.5; IR (KBr) ν~max~ 3470, 1686 cm^−1^; for ^1^H-NMR and ^13^C-NMR data, see [Table 1](#marinedrugs-13-06306-t001){ref-type="table"}; EIMS *m*/*z* 264 \[M^+^\], 249, 231, 192; HREIMS *m*/*z* 264.1721 \[M^+^\] (calculated for C~16~H~24~O~3~, 264.1720).

Peaurantiogriseol F (**6**): white solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ +21 (*c* 2.2, MeOH); UV (MeOH) λ~max~ (logε) 289 (1.9) nm; ECD (MeOH) Δε~296~ −1.61; for ^1^H-NMR and ^13^C-NMR data, see [Supplementary Materials table S1](#marinedrugs-13-06306-s001){ref-type="supplementary-material"}; EIMS *m*/*z* 282 (M^+^), 264, 249, 203, 173; HRESIMS *m*/*z* 283.18999 \[M + H\]^+^ (calculated for C~16~H~27~O~4~, 283.19039 \[M + H\]^+^).

3.5. Computational Analyses {#sec3dot5-marinedrugs-13-06306}
---------------------------

All the theoretical methods and the basis set used for optimization and spectrum calculation were recommended in previous studies \[[@B12-marinedrugs-13-06306],[@B13-marinedrugs-13-06306]\]. All the theoretical calculations, including geometry optimization, frequency analysis, and ECD spectrum prediction, were carried out with the density functional theory (DFT) and time-dependent density functional theory (TDDFT) methods in the Gaussian 09 software package \[[@B14-marinedrugs-13-06306]\]. The geometry optimizations were performed at the B3LYP/6-31+G (d) level in the gas phase. Based on the final optimized structure, the ECD spectra were calculated at the PBE1PBE-SCRF/6-311++g (d, p) level using the PCM solvent continuum models with methanol as a solvent. The theoretical predicted ECD spectra were fitted in the SpecDis software package.

3.6. Esterification Procedure {#sec3dot6-marinedrugs-13-06306}
-----------------------------

The Mosher esters of compounds **1** and **2** were prepared by treatment of compounds **1** and **2** with corresponding (*R*)-(−)-α-methoxy-α-trifluoromethylphenylacetyl chloride (1.5 equivalence ratio), or (*S*)-(+)-α-methoxy-α-trifluoromethylphenylacetyl chloride (1.5 equivalence ratio) in pyridine-*d*~5~ under a nitrogen atmosphere. The reaction mixtures were stood at room temperature for 3.5 h. Then, ^1^H NMR spectra of the samples were recorded at 400 MHz.

3.7. Inhibition of Aldose Reductase {#sec3dot7-marinedrugs-13-06306}
-----------------------------------

The method to examine the inhibition of aldose reductase was similar to the method used by Michael C. Van Zandt *et al.* \[[@B15-marinedrugs-13-06306]\]. Enzyme activity was measured by monitoring the rate of disappearance of NADPH at 340 nm. The reaction contents in a final volume of 300 μL were 6.6% *w*/*v* (NH~4~)~2~SO~4~, 33 mM NaH~2~PO4 (pH 6.6), 0.11 mM NADPH, 4.7 mM [dl]{.smallcaps}-glyceraldehyde, 0.59 μg of enzyme, 1% DMSO, and compound. Each assay was done in triplicate. Percent inhibition was calculated on the basis of enzyme activity in the presence or absence of compound.

4. Conclusions {#sec4-marinedrugs-13-06306}
==============

Polyketide decalin-derived secondary metabolites are widely found in nature \[[@B16-marinedrugs-13-06306],[@B17-marinedrugs-13-06306],[@B18-marinedrugs-13-06306]\]; Abundant polyketide decalin derivatives (**1**--**8**) from endophytic fungus 328\# from the mangrove in the South China Sea were reported in this work; their absolute configurations were established by theoretical calculations of electronic circular dichroism and NMR data analyses of Mosher ester derivatives. Compounds **1**--**8** showed low activity under our experimental conditions.
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